StudyFinder
Clear

Search Results Within Category "Heart and Vascular"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Heart and Vascular"

Advanced Heart Failure and Transplant Angina Arrhythmias Cardiac Rehabilitation Coronary Artery Disease Heart Structure Defect/Congenital Heart Defect Heart Valve Research Hypertension LVAD Peripheral Artery Disease Preventative Cardiology Pulmonary Embolism
3 Study Matches

Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE)- US Cohort is referred to as the GSR DEFINE- US Cohort study

A PROSPECTIVE, OBSERVATIONAL STUDY THAT WILL DOCUMENT THE LONG-TERM SAFETY, EFFECTIVENESS, AND DURABILITY OF RENAL DENERVATION IN A REAL-WORLD POPULATION, AGED 65 YEARS OR GREATER WITH HYPERTENSION IN THE UNITED STATES.

Contact(s):

Sarah Ackroyd - sackroy1@hfhs.org

Principal Investigator: Herbert Aronow
Principal Investigator ID: haronow1@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: N/A
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
STUDY PARTICIPANTS ARE >65 YEARS, WITH DIAGNOSED HYPERTENSION AS SEEN AND EVALUATED BY CARDIOVASCULAR INTERVENTIONALIST.
Exclusion Criteria:
THERE IS NO EXCLUSION CRITERIA IN THIS OBSERVATIONAL STUDY.
Interventions: Drug/Device: SYMPLICITY SPYRAL CATHETER
Conditions: HYPERTENSION, ISOLATED SYSTOLIC HYPERTENSION, COMBINED HYPERTENSION
Keywords: COMBINED HYPERTENSION, HYPERTENSION, ISOLATED SYSTOLIC HYPERTENSION

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov

HEART Camp Connect - R01

This study aims to promote long-term adherence to exercise in adults with heart failure with preserved ejection fraction (HFpEF) by providing an exercise coach for up to one year. We will test a virtual group and in-person group against each other and against virtual enhanced usual care.

Contact(s):

Crystal Grimshaw - cgrimsh1@hfhs.org

Principal Investigator: Steven Keteyian
Principal Investigator ID: sketeyi1@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: N/A
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis heart failure with EF >50%
• age >19 years old
• Echocardiogram within past 24 months
Exclusion Criteria:

• chest pain
• heart attack, coronary artery bypass surgery, or pacemaker implant within past 6 weeks
• ICD (defibrillator)
Interventions: Drug/Device: NA
Conditions: HFpEF
Keywords: exercise, heart failure, heart failure with preserved ejection fraction, HFpEF

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 3, Randomized, Multicenter, Double-Blind, PlaceboControlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

ACT-EARLY is a research study to see if an investigational drug, acoramidis (AG10), is safe and effective in preventing or delaying symptoms of a disease called Transthyretin Amyloidosis (ATTR).This research study will test whether acoramidis treatment in people who do not have the disease but who carry a genetic predisposition to developing the disease is safe and effective in preventing or delaying ATTR disease (genetic predisposition is also referred to as genetic variant).

Contact(s):

Kristin Clark - kclark2@hfhs.org

Principal Investigator: Celeste Williams
Principal Investigator ID: cwillia6@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: III
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Carries a specific change (mutation) in the TTR gene that is known, or strongly believed, to cause disease. However, they currently have no signs or symptoms of that disease. The participant's age must be close to the age when people with their specific TTR gene variant typically start developing symptoms. Specifically, they must be no more than 10 years younger than that expected age. They can be older than the expected age, as long as they are 75 years old or younger.
Exclusion Criteria:
No current stymptoms caused by ATTR amyloidosis. No current tratment for ATTR amyloidosis
Interventions: Drug/Device: Acoramidis
Conditions: Transthyretin Amyloidosis (ATTR)
Keywords: Acoramidis, Amyloidosis, ATTR Cardiomyopathy (ATTR-CM), ATTR Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis (ATTR)

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov